CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades of research. Previously, we have shown that GA therapy of MS induces CD8(+) T cell responses that can potentially suppress pathogenic CD4(+)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Sprog: | English |
| Udgivet: |
Public Library of Science (PLoS)
2013-01-01
|
| Serier: | PLoS ONE |
| Online adgang: | http://europepmc.org/articles/PMC3689655?pdf=render |